Shares of Dr Reddy's Laboratories dropped 6% in early trade on Friday, a day after the company reported a third-quarter profit that fell short of market estimates due to lower sales and pricing pressures in the key North American market.

Dr. Reddy's Laboratories shares fell by 6.2% after the company reported a marginal 2% YoY growth in Q3 FY25 net profit to Rs 1,413 crore. Despite robust revenue growth, Jefferies, Nuvama, and DAM Capital have diverse views on the stock,

Dr. Reddy's Laboratories Ltd.'s profit rose 2% in the third quarter of the current financial year, but missed analysts' estimates.

Shares of Dr Reddy's Laboratories fell by 5% as the company's third-quarter profit rise failed to impress investors. The stock closed lower on both BSE and NSE, wiping off a market valuation of Rs 5,399.

Dr Reddy’s Laboratories on Thursday said its consolidated net profit increased 2 per cent to Rs 1,413 crore in the third quarter ended December 31, 2024. The Hyderabad-based drug major had reported a profit of Rs 1,379 crore for the October-December period of last fiscal.

Shares of Dr Reddy's Laboratories Ltd tumbled more than 6.65 per cent to Rs 1,203.60 on Friday, with its total market capitalisation slipping below Rs 1 lakh crore mark.

Hyderabad: Despite posting record revenues, pharma major Dr Reddy's Laboratories on Thursday reported a marginal 2% increase in consolidated profit after tax (PAT attributable to equity holders) at 1,